Entera Bio (ENTX) News Today $2.10 -0.06 (-2.78%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short InterestEntera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 52,600 shares, a growth of 19.0% from the October 31st total of 44,200 shares. Based on an average daily volume of 64,200 shares, the days-to-cover ratio is presently 0.8 days.December 1, 2024 | marketbeat.comEntera Bio Ltd. (NASDAQ:ENTX) Sees Large Increase in Short InterestEntera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 44,200 shares, an increase of 9.4% from the October 15th total of 40,400 shares. Based on an average trading volume of 31,500 shares, the days-to-cover ratio is currently 1.4 days.November 17, 2024 | marketbeat.comHC Wainwright Decreases Earnings Estimates for Entera BioEntera Bio Ltd. (NASDAQ:ENTX - Free Report) - HC Wainwright dropped their FY2024 earnings per share estimates for Entera Bio in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0November 14, 2024 | marketbeat.comEntera Bio Buy Rating: Strong Financials, Strategic Developments, and Promising Pipeline Drive Analyst ConfidenceNovember 12, 2024 | markets.businessinsider.comEntera Bio's (ENTX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Entera Bio in a report on Monday.November 11, 2024 | marketbeat.comEntera Bio Highlights Q3 2024 Financials and FDA AnticipationNovember 9, 2024 | markets.businessinsider.comEntera Bio Reports Q3 2024 Financial Results and Provides Business UpdatesNovember 8, 2024 | globenewswire.comEntera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 14.4% in OctoberEntera Bio Ltd. (NASDAQ:ENTX - Get Free Report) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 40,400 shares, a drop of 14.4% from the September 30th total of 47,200 shares. Based on an average daily volume of 37,300 shares, the days-to-cover ratio is currently 1.1 days.October 29, 2024 | marketbeat.comEntera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 38.4% in SeptemberEntera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 47,200 shares, an increase of 38.4% from the September 15th total of 34,100 shares. Based on an average trading volume of 41,000 shares, the short-interest ratio is presently 1.2 days.October 13, 2024 | marketbeat.comBuy Rating Affirmed for Entera Bio’s EB613: A Game Changer in Osteoporosis TreatmentOctober 8, 2024 | markets.businessinsider.comEntera Bio (NASDAQ:ENTX) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Entera Bio in a research report on Monday.October 7, 2024 | marketbeat.comEntera Bio's (ENTX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Entera Bio in a report on Friday.September 27, 2024 | marketbeat.comEntera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic DisordersSeptember 25, 2024 | globenewswire.comQuantum Genomics Société Anonyme (2QG.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comEntera Bio Ltd. (NASDAQ:ENTX) Short Interest UpdateEntera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 27,800 shares, an increase of 11.6% from the July 31st total of 24,900 shares. Based on an average trading volume of 56,100 shares, the days-to-cover ratio is presently 0.5 days.September 1, 2024 | marketbeat.comWe're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn RateAugust 30, 2024 | finance.yahoo.comEntera Bio to Participate in Upcoming Investor and Scientific ConferencesAugust 20, 2024 | globenewswire.comEntera Bio Ltd. Forecasted to Earn Q3 2024 Earnings of ($0.05) Per Share (NASDAQ:ENTX)Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Investment analysts at HC Wainwright lifted their Q3 2024 earnings per share estimates for shares of Entera Bio in a report issued on Monday, August 12th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.05)August 15, 2024 | marketbeat.comEntera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 51.0% in JulyEntera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 24,900 shares, a decrease of 51.0% from the July 15th total of 50,800 shares. Based on an average daily trading volume, of 78,300 shares, the short-interest ratio is currently 0.3 days.August 13, 2024 | marketbeat.comEntera Bio Receives Strong Buy Rating Amid Anticipated FDA Ruling and Pipeline ProgressAugust 12, 2024 | markets.businessinsider.comEntera Bio (NASDAQ:ENTX) Releases Earnings ResultsEntera Bio (NASDAQ:ENTX - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of $0.06 million during the quarter.August 12, 2024 | marketbeat.comEntera Bio Ltd.: Entera Bio Reports Q2 2024 Financial Results and Provides Business UpdatesAugust 11, 2024 | finanznachrichten.deEntera Bio Reports Q2 2024 Financial Results and Provides Business UpdatesAugust 9, 2024 | globenewswire.comEntera Bio (NASDAQ:ENTX) Stock Price Up 1.9%Entera Bio (NASDAQ:ENTX) Trading 1.9% HigherAugust 1, 2024 | marketbeat.com3 Meme Stocks That Can Surge by 200% Before 2025July 8, 2024 | investorplace.com3 Clinical-Stage Biotech Stocks to Buy for Multibagger ReturnsJuly 2, 2024 | investorplace.com3 Meme Stocks to Buy on the Dip: June 2024June 25, 2024 | investorplace.com7 Penny Stocks to Turn $3 Into $1 Million Within 36 MonthsJune 20, 2024 | investorplace.comRag to Riches: 3 Penny Stocks That Could Make Early Investors RichJune 20, 2024 | investorplace.com3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024June 17, 2024 | investorplace.comUnder-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024June 10, 2024 | investorplace.comMeme Mania Meets Medicine: 3 Biotech Stocks Primed to SoarJune 7, 2024 | investorplace.comThe Next Novavax? 3 Biopharma Stocks to Buy Before They BoomMay 23, 2024 | investorplace.comEntera Bio Ltd (ENTX)May 17, 2024 | investing.comHC Wainwright Analysts Decrease Earnings Estimates for Entera Bio Ltd. (NASDAQ:ENTX)Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Equities researchers at HC Wainwright cut their Q4 2024 earnings estimates for Entera Bio in a research note issued to investors on Monday, May 13th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.07) per shaMay 15, 2024 | marketbeat.comEntera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board MemberMay 15, 2024 | globenewswire.comPositive Outlook for Entera Bio with Buy Rating and Promising Pipeline DevelopmentsMay 13, 2024 | markets.businessinsider.comEntera Bio's (ENTX) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Entera Bio in a report on Monday.May 13, 2024 | marketbeat.comEntera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024May 13, 2024 | globenewswire.comENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024May 10, 2024 | investorplace.comEntera Bio Reports Q1 2024 Financial Results and Provides Business UpdatesMay 10, 2024 | globenewswire.comAre Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?April 30, 2024 | finance.yahoo.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 15, 2024 | investorplace.comEntera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 988.9% in MarchEntera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 88,200 shares, an increase of 988.9% from the March 15th total of 8,100 shares. Based on an average daily trading volume, of 161,500 shares, the short-interest ratio is presently 0.5 days.April 10, 2024 | marketbeat.comEntera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral ResearchApril 8, 2024 | globenewswire.comQ1 2024 EPS Estimates for Entera Bio Ltd. (NASDAQ:ENTX) Lifted by HC WainwrightEntera Bio Ltd. (NASDAQ:ENTX - Free Report) - Research analysts at HC Wainwright raised their Q1 2024 earnings per share (EPS) estimates for shares of Entera Bio in a note issued to investors on Tuesday, April 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.April 4, 2024 | marketbeat.comEntera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsMarch 26, 2024 | globenewswire.comWe Think Entera Bio (NASDAQ:ENTX) Can Afford To Drive Business GrowthMarch 23, 2024 | finance.yahoo.comEntera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel SyndromeMarch 20, 2024 | globenewswire.comEntera Bio Ltd.: Entera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesMarch 12, 2024 | finanznachrichten.de Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW ENTX Media Mentions By Week ENTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTX News Sentiment▼0.000.60▲Average Medical News Sentiment ENTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTX Articles This Week▼01▲ENTX Articles Average Week Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Valneva News Today C4 Therapeutics News Today 4D Molecular Therapeutics News Today COMPASS Pathways News Today Immutep News Today AC Immune News Today Larimar Therapeutics News Today Amylyx Pharmaceuticals News Today Lifecore Biomedical News Today iTeos Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
